News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Investor Alerts Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard August 16, 2022 Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium August 4, 2022 Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update August 2, 2022 Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference July 28, 2022 Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update July 6, 2022 Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén June 28, 2022 Immunic to Participate in Industry and Scientific Conferences in July June 15, 2022 Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology June 8, 2022 Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June June 2, 2022 Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update May 10, 2022 Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update Show 5102550100 per page«1…45678910…19»
